HomeCompareBNOX vs BTI

BNOX vs BTI: Dividend Comparison 2026

BNOX yields 790.20% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOX wins by $2499878.54M in total portfolio value
10 years
BNOX
BNOX
● Live price
790.20%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2499878.58M
Annual income
$2,001,595,404,407.55
Full BNOX calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — BNOX vs BTI

📍 BNOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOX
Annual income on $10K today (after 15% tax)
$67,167.13/yr
After 10yr DRIP, annual income (after tax)
$1,701,356,093,746.42/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, BNOX beats the other by $1,701,356,091,364.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOX + BTI for your $10,000?

BNOX: 50%BTI: 50%
100% BTI50/50100% BNOX
Portfolio after 10yr
$1249939.31M
Annual income
$1,000,797,703,604.92/yr
Blended yield
80.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

BNOX
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$6.00
+2270.6% upside vs current
Range: $6.00 — $6.00
Altman Z
-82.3
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOX buys
0
BTI buys
0
No recent congressional trades found for BNOX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOXBTI
Forward yield790.20%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$2499878.58M$37.8K
Annual income after 10y$2,001,595,404,407.55$2,802.29
Total dividends collected$2460392.87M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$6.00$40.00

Year-by-year: BNOX vs BTI ($10,000, DRIP)

YearBNOX PortfolioBNOX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$89,720$79,020.15$11,301$601.08+$78.4KBNOX
2$758,589$662,588.76$12,799$706.58+$745.8KBNOX
3$6,047,418$5,235,727.31$14,527$832.38+$6.03MBNOX
4$45,478,990$39,008,252.73$16,527$982.75+$45.46MBNOX
5$322,828,490$274,165,970.92$18,846$1,162.95+$322.81MBNOX
6$2,164,251,074$1,818,824,589.26$21,545$1,379.49+$2164.23MBNOX
7$13,711,496,364$11,395,747,714.83$24,694$1,640.41+$13711.47MBNOX
8$82,145,270,460$67,473,969,350.51$28,378$1,955.69+$82145.24MBNOX
9$465,685,208,688$377,789,769,296.29$32,702$2,337.79+$465685.18MBNOX
10$2,499,878,577,704$2,001,595,404,407.55$37,794$2,802.29+$2499878.54MBNOX

BNOX vs BTI: Complete Analysis 2026

BNOXStock

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this BNOX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOX vs SCHDBNOX vs JEPIBNOX vs OBNOX vs KOBNOX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.